Ed Schnipper, M.D.
President and CEO, Cellgate
Dr. Schnipper is the President and Chief Executive Officer of Cellgate, a pharmaceutical development company focused on the development of new cancer medicines in the field of oncology. Dr. Schnipper has more than 15 years of management experience in the clinical development of medicines for the pharmaceutical and biotechnology industries. Dr. Schnipper has been responsible for numerous clinical trial programs that served to support successful New Drug Application (NDA) strategies and competitive market positions for new therapeutic products.
Prior to joining Cellgate, Dr. Schnipper was Vice President of Clinical Development at ALZA Corporation, a specialty pharmaceutical company. In this role, Dr. Schnipper was responsible for overseeing all aspects of the clinical strategy for new pharmaceutical products, as well as the Phase IV strategies for products in both the company's pipeline and the pharmaceutical product portfolio. While at ALZA, he provided input on R&D efforts and marketing programs, acted as a spokesperson on company affairs to diverse external audiences and provided guidance to scientific and medical advisory boards for the company.
Prior to his role at ALZA, Dr. Schnipper served as Senior Vice President and Medical Director at SEQUUS Pharmaceuticals, where he was responsible for clinical and regulatory functions as a member of the Executive Committee. Between 1983 and 1996, Dr. Schnipper held various positions at Hoffmann-La Roche, culminating in Vice President of Clinical Operations, Virology.
Dr. Schnipper earned his B.S. degree from Hobart College in Geneva, New York, and his M.D. from the Georgetown University School of Medicine in Washington, D.C. He trained in medicine at the Long Island Jewish-Hillside Medical Center and completed fellowships in hematology at New York University and medical oncology at Memorial Sloan-Kettering Cancer Center in New York. He is a member of the American Society of Clinical Oncology and the American Academy of Pharmaceutical Physicians, among others.
Daniel F. Hoth, M.D.
Dr. Hoth is a consultant to the pharmaceutical and biotech industry in the
areas of drug development and clinical trials. He is a medical oncologist
with more than 25 years' experience in clinical development of
investigational drugs in cancer and infectious disease. Most recently, he
served as Senior Vice President, Development, and Chief Medical Officer of
Axys Pharmaceuticals. Prior to that, he was at Cell Genesys as Senior Vice
President and Chief Medical Officer (1993–1997). From 1987 to 1993 he was
Director, Division of AIDS, at the National Institute of Allergy and
Infectious Disease, and from 1980 to 1987 at the National Cancer Institute
as Chief, Investigational Drug Branch, responsible for all clinical
investigations of IND stage anticancer pharmaceuticals.
Dr. Hoth currently serves on several clinical/scientific advisory boards and the boards of directors of three companies. He has participated in four NDAs. He has experience developing small molecules, antibodies, cytokines, gene therapy and vaccines, and has also served as a consultant to both the FDA and NIH in oncology drug development.
Frank McCormick, Ph.D.
Director, UCSF Cancer Research Institute
Dr. McCormick is a molecular biologist and nationally recognized research scientist in cancer biology. Dr. McCormick is currently the Director of the UC San Francisco (UCSF) Cancer Research Institute, Director and Associate Dean of the UC San Francisco Comprehensive Cancer Center and Professor, UC San Francisco Department of Microbiology and Immunology.
Prior to UCSF, Dr. McCormick founded ONYX Pharmaceuticals, Inc., a biotechnology company focused on developing new cancer therapies. Dr. McCormick also served as Vice President, Therapeutic Research, at Chiron Corporation before ONYX and Vice President, Discovery Research, at Cetus Corporation.
Frank E. Stockdale, M.D., Ph.D.
Comprehensive Cancer Center, Stanford University
Dr. Stockdale is a Maureen Lyles D'Ambrogio Professor of Medicine Emeritus (active) and Professor of Biological Sciences, and former Josephine Knotts Knowles Professorship in Human Biology (1990–1996). He is an internationally known cell and developmental biologist as well as a renowned cancer specialist. He has clinical teaching and cancer patient care commitments at Stanford Medical Center and Stanford Cancer Center, where, as a member of the faculty of the School of Medicine, he founded and directed the Combined Modalities Breast Cancer Program.
Dr. Stockdale’s practice is limited to the diagnosis and treatment of breast cancer. In particular, he provides consultation and treatment at the time of diagnosis and prior to surgical intervention for breast cancer; for locally advanced and inflammatory breast cancer; or at the recurrence of breast cancer.
Born in California, Dr. Stockdale did his undergraduate work at Yale University and received his M.D. and Ph.D. degrees from the University of Pennsylvania. Prior to coming to Stanford, he was at Case Western Reserve University and the National Institutes of Health.
The focus of Dr. Stockdale's research is on understanding the cellular, biochemical and molecular genetic mechanisms for regulation of diversification of cells during development. His recent research deals with the cellular and molecular mechanisms that specify the fates of diverse cell types in development. His research provides insights into the formation and growth of tissues and contributes to our understanding of the genetic and developmental bases of normal and abnormal forms of growth. He carries out a number of clinical investigations in the management of breast cancer that are conducted at the national level. A former Guggenheim fellow, Dr. Stockdale serves on a number of advisory bodies for scientific societies and governmental agencies.
Allan I. Basbaum, Ph.D.
Professor and Chair, Department of Anatomy, UC San Francisco
Dr. Basbaum is a founder and member of BiPar Science’s Scientific Advisory Board. He is currently Professor and Chair, Department.of Anatomy, UC San Francisco. Other academic positions have included Professor and Vice-Chair, Department of Anatomy, UC San Francisco (joint appointment in the Department of Physiology and W. M. Keck Foundation Center for Integrative Neurosciences), and Associate Professor, Departments of Anatomy and of Physiology, UC San Francisco.
Dr. Basbaum received a B.S. from McGill University in 1968 and a Ph.D. from the University of Pennsylvania in Anatomy and Psychology in 1972, and did postdoctoral research in Neurophysiology at the University College London and in neuroanatomy at the University of California San Francisco.
Keith Yamamoto, Ph.D.
Executive Vice Dean, School of Medicine, UC San Francisco
Keith Yamamoto, Ph.D. is a Professor of Cellular/Molecular Pharmacology and Biochemistry/Biophysics at UCSF. He has been with UCSF for nearly 30 years and has received numerous honors and awards. He is an elected Fellow, American Association for the Advancement of Science (2002) and Institute of Medicine (2003).
He has published many articles in the field of cellular/molecular pharmacology.
He currently oversees the Yamamoto Lab, which is interested in mechanisms by which gene transcription is regulated in different cell types and physiological (or pathological) setting; and mechanisms that control fundamental biological processes, including development, cell differentiation, responses to environmental signals and stresses, senescence and disease.
Dr. Yamamoto did his postdoctorate studies at UCSF, Molecular Biology. He received his Ph.D. in Biochemical Sciences from Princeton University and did his undergraduate studies at Iowa State University.
Read about our management team
Read about our Board of Directors
Read about our current investors
